Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632131 | 1.00 | ALDH1A1 (0.69) | ALDH1A1GAALMNAKDM4ETSHR | |
| SCHEMBL12310310 | 1.00 | ALDH1A1 (0.69) | ALDH1A1GAALMNAKDM4ETSHR | |
| SCHEMBL12310361 | 0.96 | ALDH1A1 (0.64) | ALDH1A1GAALMNAKDM4ETSHR | |
| SCHEMBL1723878 | 0.92 | TSHR (0.59) | ALDH1A1GAATSHR | |
| SCHEMBL1723696 | 0.92 | TSHR (0.59) | ALDH1A1GAATSHR | |
| SCHEMBL1724880 | 0.92 | TSHR (0.59) | ALDH1A1GAATSHR | |
| SCHEMBL29859252 | 0.92 | TSHR (0.59) | ALDH1A1GAATSHR | |
| SCHEMBL3631759 | 0.92 | TSHR (0.59) | ALDH1A1GAATSHR | |
| SCHEMBL14353631 | 0.92 | TSHR (0.59) | ALDH1A1GAATSHR | |
| SCHEMBL1723692 | 0.92 | TSHR (0.59) | ALDH1A1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | ALDH1A1 4556/4885GAA 1981/4885LMNA 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.